Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606801 · ClinicalTrials.gov registry record · NA
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT00606801 is a NA study that has completed, run by Yale University. The registered enrollment target is 34 participants.
The verdict
NCT00606801, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these effects may result in improved cognitive performance in a group of subjects known to have impaired performance in various cognitive tasks.
Interventions
- DRUG placebo
- DRUG Galantamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606801
The ClinicalTrials.gov registry entry for NCT00606801 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00606801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606801 about?
NCT00606801 is a clinical study titled "Galantamine Effects on Cognitive Function in Abstinent Cocaine Users". To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these effects may result in improv...
What is the current status of trial NCT00606801?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2007-06. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00606801?
The interventions under investigation include: placebo (DRUG), Galantamine (DRUG).
Who is sponsoring clinical trial NCT00606801?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.